Journal of Experimental Therapeutis and Oncology - Journal - Bridge of Knowledge

Journal of Experimental Therapeutis and Oncology

ISSN:

1359-4117

eISSN:

1533-869X

Disciplines
(Field of Science):

biomedical engineering (Engineering and Technology)
medical biology (Medical and Health Sciences )
pharmacology and pharmacy (Medical and Health Sciences )
medical sciences (Medical and Health Sciences )
health sciences (Medical and Health Sciences )
biotechnology (Natural sciences)
biological sciences (Natural sciences)
chemical sciences (Natural sciences)

expand collapse

Ministry points: Help

Ministry points - current year
Year	Points	List
Year 2024	20	Ministry scored journals list 2024

expand collapse

Ministry points - previous years
Year	Points	List
2024	20	Ministry scored journals list 2024
2023	20	Ministry Scored Journals List
2022	20	Ministry Scored Journals List 2019-2022
2021	20	Ministry Scored Journals List 2019-2022
2020	20	Ministry Scored Journals List 2019-2022
2019	20	Ministry Scored Journals List 2019-2022
2016	0	foreign scientific journals
2015	0	foreign scientific journals
2014	0	foreign scientific journals
2013	0	foreign scientific journals
2012	0	foreign scientific journals

Model:

Traditional

Points CiteScore:

Points CiteScore - current year
Year	Points
Year 2022	0

expand collapse

Points CiteScore - previous years
Year	Points
2022	0
2021	1.4
2020	1.2
2019	1.1
2018	0.9
2017	0.8
2016	0.9
2015	2.3
2014	2.9
2013	2.4
2012	2.2
2011	3

Impact Factor:

n/a

Sherpa Romeo:

https://v2.sherpa.ac.uk/id/publication/13267

Papers published in journal

results on page:
year:
- selected sort by year newest first
- sort by year oldest first
title:
- selected sort by title A-Z
- sort by title Z-A
citation:
- sort by citation descending
- sort by citation ascending

Filters

total: 1

Year 2011

Triazoloacridone C-1305 abrogates the restriction checkpoint in cells lacking functional p53 and promotes their accumulation in the G2/M phase of the cell cycle
Publication
- M. Mauer
- O. Komina
- A. Składanowski
- J. Wesierska-Gadek
- Journal of Experimental Therapeutis and Oncology - Year 2011
Triazoloakrydon C-1305, nowy inhibitor topoizomerazy II, wykazuje wysoką aktywość cytotoksyczną wobec komórek wielu typów nowotworów. Komórki mysie pozbawione genu PARP-1 wykazywały nadwrażliwość na działanie tego związku. W pracy testowaliśmy działanie związku wobec dwóch różnych komóek nowotworowych różniących się statusem p53: komórkami białaczki myelocytarnej HL-60 i raka sutka MCF-7. Wykazaliśmy, że inkubacja ze związkiem...

Full text to download in external service

seen 315 times